New Dual-Action antibody shows promise for tough lymphoma cases
NCT ID NCT05189093
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 25 times
Summary
This early-phase trial tested a new drug called HX009 in 48 adults with lymphoma that returned or didn't respond to prior treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help cancer hide from the immune system. The goal was to see if the drug could shrink tumors and how safe it was, but since patients may need ongoing therapy, this is considered disease control, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Sciense
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.